Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy

End-stage nonobstructive hypertrophic cardiomyopathy (HCM), with systolic dysfunction and adverse left ventricular (LV) remodeling due to extensive myocardial scarring, is associated with high risk for progressive heart failure and mortality [(1–5)][1]. Currently, heart transplantation is the only